Addiction is a primary, chronic and relapsing brain disease characterized by a person pathologically pursuing reward and/or relief by substance use and other behaviors, according to the American Society of Addiction Medicine (ASAM).
Opioids are a class of drugs that interact with opioid receptors on nerve cells in the brain and nervous system to produce pleasurable effects and relieve pain. Opioids include heroin as well as the prescription pain relievers oxycodone, hydrocodone, codeine, morphine, fentanyl and others. Prescription pain relievers are often necessary for treatment of acute and chronic pain, but with continued use the body can potentially build physical dependence and tolerance.
Opioid addiction is the fastest growing public health crisis in America today.
Each day in the US, 116 people die from opioid-related causes.2
Opioid overdose is the leading cause of death for Americans under the age of 50.1
More than 63,000 Americans died from drug overdoses in 2016, most involving a prescription painkiller or an illicit opioid like heroin.2
The true cost of the opioid drug epidemic in 2015 was $504 billion, or roughly half a trillion dollars, according to the U.S. Council of Economic Advisers.3
Women and adolescents are especially at risk for developing opioid addiction: women are more likely than men to be prescribed painkillers at higher doses and the use among adolescents is growing at an alarming rate according to the American Society of Addiction Medication (ASAM).4
In 2015, there were 690,000 OUD ICU admissions with an average cost of $92,400 per patient, totaling an average cost to payers of $63.8B.5
Buprenorphine is an FDA-approved medication that can help treat opioid addiction. It binds to opioid receptors and effectively blocks the signals from other opioids. Currently, oral buprenorphine is the most commonly used form of buprenorphine-based medication-assisted therapy for the treatment of OUD. Patients receiving oral buprenorphine typically receive once-daily oral buprenorphine or buprenorphine/naloxone combination products (either tablets or sublingual film). These formulations are self-administered.
Braeburn develops long-acting medicines for treating
opioid use disorder.
1 Centers for Disease Control and Prevention. CDC Wonder. Accessed on February 19, 2018. https://wonder.cdc.gov/controller/datarequest/D76
2 NCHS, National Vital Statistics System, Mortality. Accessed on June 10, 2018, https://www.cdc.gov/nchs/data/databriefs/db294_table.pdf#4
3 The Council of Economic Advisors, November 2017. The Underestimated Cost of the Opioid Crisis. Accessed on January 18, 2018, https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The%20Underestimated%20Cost%20of%20the%20Opioid%20Crisis.pdf
4 American Society of Addiction Medicine. Opioid Addiction 2016 Facts and Figures. Accessed on June 10, 2018. https://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf
5 Stevens et al, 2017, Annals of the American Thoracic Society